Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) insider Sherry Korczynski sold 8,750 shares of the company’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the transaction, the insider owned 235,689 shares in the company, valued at approximately $1,230,296.58. This represents a 3.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Aquestive Therapeutics Stock Performance
Aquestive Therapeutics stock opened at $4.78 on Friday. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $7.55. The firm has a 50 day moving average price of $4.39 and a 200 day moving average price of $4.26. The company has a market capitalization of $599.94 million, a PE ratio of -7.35 and a beta of 1.48.
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million. As a group, equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.
Analysts Set New Price Targets
Read Our Latest Analysis on AQST
Institutional Trading of Aquestive Therapeutics
A number of large investors have recently modified their holdings of AQST. NewEdge Advisors LLC purchased a new position in Aquestive Therapeutics in the third quarter valued at $28,000. BNP Paribas Financial Markets increased its holdings in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares during the period. Modern Wealth Management LLC acquired a new stake in Aquestive Therapeutics in the 2nd quarter valued at about $33,000. Elevation Point Wealth Partners LLC acquired a new stake in Aquestive Therapeutics in the 1st quarter valued at about $42,000. Finally, ADAR1 Capital Management LLC boosted its stake in shares of Aquestive Therapeutics by 103.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after buying an additional 264,000 shares during the period. Hedge funds and other institutional investors own 32.45% of the company’s stock.
About Aquestive Therapeutics
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
See Also
- Five stocks we like better than Aquestive Therapeutics
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
